UMN Pharma Inc. clinical trials
Acquired by Shionogi, Dec 2019 · source ↗
The registry lists 8 studies whose lead sponsor is UMN Pharma Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2017.
Before and after it joined Shionogi
- First submitted before UMN Pharma Inc. became part of Shionogi
- 8
- First submitted after UMN Pharma Inc. became part of Shionogi
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- UMN Pharma Inc.8 studies
Something wrong with this grouping? Tell us on the Shionogi page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Shionogi studies →
- A Study to Evaluate Intramuscular ASP7374CompletedNCT01961960Phase 3
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi
- A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or OlderCompletedNCT02366962Phase 3
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi
- Phase-3 Study of ASP7374, Cell-culture-derived Influenza VaccineCompletedNCT01767896Phase 3
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi
- A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult VolunteersCompletedNCT01450579Phase 2
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi
- A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult VolunteersCompletedNCT01393951Phase 1/2
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi
- Study of ASP7374, Cell-culture-derived Influenza VaccineCompletedNCT01961947Phase 3
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi
- Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed AdultsCompletedNCT01195038Phase 2
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi
- Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young AdultsCompletedNCT00980447Phase 2
Sponsor listed in the registry: UMN Pharma Inc. · First submitted before UMN Pharma Inc. became part of Shionogi